

# Curriculum Vitae

## 1. Personal Data

First name: **Giovanni**

Last name: **Martinelli**

Title: **Scientific Director**

Institution: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS

Address of Institution: Via P. Maroncelli,40 – 47014, Meldola (FC), Italy

---

## 2. Contacts

Mobile: +39-348-7704650

e-mail: giovanni.martinelli@irst.emr.it

---

## 3. Education (Laurea or other professional education, include post doctoral training)

**First Degree:** Graduated in Medicine

Name of Institution: University of Verona Medical School

City, Country: Verona, Italy

Date: 1985

Name of Institution	City, Country	Date	Specializations
University of Verona	Verona, Italy	in 1988	Hematology
University of Verona	Verona, Italy	in 1992	Medical Genetics

Registration medical register (Verona Italy): year 1986, n° 4900.

*20 July 2001*

Suitable to the role of **Associate University Professor**, scientific field disciplinary F07G – **Malattie del Sangue**, on the Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano.

---

## 4. Research and/or professional experience

List, in chronological order, present and previous employment, experience, certifications, and honors. Include present membership on any Governmental or Advisory Committee/Boards.

*January 1984-1988*

**Research and clinical training as Resident Physician, Institute of Medical Pathology (Division of Hematology, University of Verona Medical School).** The main scientific interest regarded the field of hematological malignancies, in particular leukemias and lymphomas. During this period he learned patient management and diagnosis, the monitoring of infections and therapy in immunocompromised patients. He performed and monitored autologous bone marrow transplantation in neoplastic patients, immunotyped bone marrow cells with monoclonal antibodies, and determined levels of interferon and interleukins in patients samples.

*June 1988-November 1988*

**Specialist in Hematology**, U.S.L. 31, District of Mantova City, Italy, and U.S.L. 29, District of Volta Mantovana, Italy.

*1989*

**Specialist in General Hematology**, U.S.L. 47, Mantova, Italy.

*1990-1991*

Research and clinical training, Institute of Biological Sciences, University of Verona.

*1991-1993*

Research and clinical training, Institute of Hematology and Oncology "Seràgnoli", University of Bologna.

*January 1993 - 2005*

**Medical Doctor for Prof. Sante Tura and Prof. Michele Baccarani, Institute of Hematology "L. e A. Seràgnoli", University of Bologna Medical School. Responsible of the Laboratory of Molecular Biology.** Main fields of research: acute leukemia, chronic myeloid leukemia: research of target therapies in the major haematological syndromes: therapy of acute leukemias, therapy of chronic myeloid leukemias Ph<sup>+</sup> and not Ph<sup>+</sup>, and therapy of Hypereosinophilic syndrome (HES).

*2005 - 2017*

**Associate Professor in Hematology** –, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna. **Responsible of the Laboratory of Molecular Biology**, Institute of Hematology "L. and A. Seràgnoli".

**Main fields of research:** acute leukemia, chronic myeloid leukemia: research of target therapies in the major haematological syndromes: therapy of acute leukemias, therapy of chronic myeloid leukemias Ph<sup>+</sup> and not Ph<sup>+</sup>, and therapy of Hypereosinophilic syndrome (HES).

**Clinical Activity:** Conduction of several Phase I, Phase II, and Phase III clinical trials on AML, LAL, and CML as Principal Investigator; Studies with compassionate use of drugs with good knowledge of Good Clinical Practice.

*From 1<sup>st</sup> January 2018 – present*

Scientific Director - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS

### **Research interests**

His research and clinical activity involve the area of acute and chronic myeloid leukemia (AML and CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS). Expertise: Conduction of several Phase I-II-III clinical trials and biological research projects on AML, ALL, MDS and CML as Principal Investigator, with good knowledge of Good Clinical Practice. He has the skills, expertise and authority to lead a team and he has the capacity of using the resources in a flexible way, to achieve the project objectives.

### **Association Membership**

- Società Italiana di Ematologia Sperimentale (SIES)  
Member and Vice President of the Consiglio Direttivo SIES
- Società Italiana di Ematologia (SIE)

- American Society of Haematology (ASH)
- American Association for the Advancement of Sciences (AAAS)
- American Association for Cancer Research (AACR)
- European Haematology Association (EHA)
- American Society of Clinical Oncology (ASCO)
- European Association for Cancer Research (EACR)
- European LeukemiaNet (Progetto Europeo VI PQ)
- Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA)
- Working Party Leucemie Acute
- COST Action BM0801 (EuGESMA)

## Reviewing Activities

- Haematologica
- Leukemia
- Blood
- American Journal of Hematology
- Clinical Leukemia
- Cancer
- Hematological Oncology
- Neoplasia
- Annals of Hematology
- **Editor-in-Chief:** Hematology Reports

## 5. Projects

Co-operator in the following Research projects MURST - COFIN 2001 – 2002 – 2003; Ricerca fondamentale orientata 2002 – 2003; Principal proposed in the RFO 60% 2007 and 2008; FIRB 2001 – 2003 projects. Scientific Responsible in the FIRB 2006 project.

Principal Investigator AIRC Grant Proposal 2004, AIRC 2007, AIRC 2010.

Responsible for Research Unit of PRIN 2008 project; Scientific Responsible of two projects on Bando Ministero Salute 2009, and one project on Bando Ministero Salute Ricerca Finalizzata 2009.

### **FP7-HEALTH-2012-INNOVATION-1 Seventh framework programme 2011**


Proponent and Principal Investigator of financed International project: “Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia - NGS-PTL”.

### **Innovative Medicine Initiative 2**

Responsible of Work Package in the financed International project: “Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology – HARMONY” (Project starting January 2017).

Principal Investigator of the AIRC Investigator Grant 2016 “Beating aneuploid acute leukemia by integrated genomic, functional and preclinical studies”.

Date, November 26, 2018

Giovanni Martinelli  


## BIBLIOGRAPHY

1. [Mancini M](#), [Brusa G](#), [Zuffa E](#), [Corrado P](#), [Martinelli G](#), [Grafone T](#), [Barbieri E](#), [Santucci MA](#). Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. *Leuk Res.* 31(7):979-87, 2007.  
Impact Factor 2.606 Citation index 20
2. [Martinelli G](#). Atypical chronic myeloproliferative disorders: genes and imatinib-sensitive targets. *Semin Hematol.* 44(2 Suppl 2):S1-3, 2007.  
Impact Factor Citation index
3. [Martinelli G](#), [Rondoni M](#), [Ottaviani E](#), [Paolini S](#), [Baccarani M](#). Hypereosinophilic syndrome and molecularly targeted therapy. *Semin Hematol.* 44(2 Suppl 2):S4-S16, 2007.  
Impact Factor 4.438 Citation index 3
4. Bussolari R, Candini O, Colomer D, Corradini F, Guerzoni C, mariani S, Castellano S, Silvestri C, Pecorari L, Iacobucci I, Soverini S, Fasano T, [Martinelli G](#), Cervantes, Calabretta B. Coding sequence and intron-exon junctions of the c-myc gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukaemia patients. *Leuk Res.* 31(2):163-7, 2007.  
Impact Factor 2.39 Citation index 2
5. [Iacobucci I](#), [Galletti L](#), [Amabile M](#), [Soverini S](#), [Baccarani M](#), [Martinelli G](#). Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. *Haematologica* 92(3):429-30, 2007.  
Impact Factor 5.978 Citation index 1
6. Malagola M, Damiani D, [Martinelli G](#), Michelutti A, Cesana B, De Vivo A, Piccaluga PP, Ottaviani E, Candoni A, Geromin, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Fili C, Baccarani M, Russo D. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. *British Journal of Haematology*, 136(1):87-95, 2007.  
Impact Factor 4.478 Citation index 15
7. [Tazzari PL](#), [Tabellini G](#), [Bortul R](#), [Papa V](#), [Evangelisti C](#), [Grafone T](#), [Martinelli G](#), [McCubrey JA](#), [Martelli AM](#). The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. *Leukemia*, 21(5):886-96, 2007.  
Impact Factor 8.634 Citation index 60
8. [Soverini S](#), [Colarossi S](#), [Gnani A](#), [Castagnetti F](#), [Rosti G](#), [Bosi C](#), [Paolini S](#), [Rondoni M](#), [Piccaluga PP](#), [Palandri F](#), [Giannoulia P](#), [Marzocchi G](#), [Luatti S](#), [Testoni N](#), [Iacobucci I](#), [Cilloni D](#), [Saglio G](#), [Baccarani M](#), [Martinelli G](#). Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. *Haematologica* 92(3):401-4, 2007.  
Impact Factor 5.032 Citation index 112
9. [Piccaluga PP](#), [Ascani S](#), [Agostinelli C](#), [Paolini S](#), [Laterza C](#), [Papayannidis C](#), [Martinelli G](#), [Visani G](#), [Baccarani M](#), [Pileri SA](#). Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature. *Histopathology*, 50(6):802-5, 2007.

Impact Factor 4.131 Citation index 6

10. Potenza L, Luppi M, Riva G, Ottaviani E, Zucchini P, Morselli M, Volzone F, Forghieri F, **Martinelli G**, Torelli G. [May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t\(8;21\) AML?](#) *Leuk Res.* Feb;31(2):269-71, 2007.

Impact Factor 2.39 Citation index 1

11. [Soverini S, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F, Paolini S, Rosti G, Baccarani M.](#) Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. *Lancet Oncol.* 8(3):273-4, 2007.

Impact Factor 13.283 Citation index 29

12. [Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Bapapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D.](#) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR $\alpha$  positive chronic eosinophilic leukemia. *Blood.* 109(11):4635-40, 2007.

Impact Factor 10.432 Citation index 118

13. **Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G.** Impact of age in the outcome of patients with CML in late CP: Results of a phase II study of the GIMEMA CML WP. *Haematologica*, 92(1):101-5, 2007.

Impact Factor 5.978 Citation index 30

14. [Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, Martelli AM.](#) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. *Leukemia.* 21(3):427-38, 2007.

Impact Factor 8.634 Citation index 99

15. [Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foa R, Baccarani M, Mandelli F.](#) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. *Blood.* 109(9):3676-8, 2007.

Impact Factor 10.432 Citation index 137

16. [Palandri F, Amabile M, Rosti G, Bandini G, Benedetti F, Usala E, Angelucci E, Tiribelli M, Fanin R, Martinelli G, Baccarani M.](#) Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. *Bone Marrow Transplant.* 39(3):189-91, 2007.

Impact Factor 3.4 Citation index 10

17. [Rosti G, Martinelli G, Baccarani M.](#) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. *Nat Med.* 13(1):15; author reply 15-6, 2007.

Impact Factor 27.443 Citation index 33

18. **Piccaluga PP, Finelli C, Vigna E, Agostinelli C, Bacci F, Radiai S, Papayannidis C, Laterza C, Martinelli G, Pileri SA, Baccarani M.** Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. *Journal of Clinical Pathology* 60:581-582, 2007.

Impact Factor 2.342 Citation index 3

19. [Cilloni D](#), [Messa F](#), [Martinelli G](#), [Gottardi E](#), [Arruga F](#), [Defilippi I](#), [Carturan S](#), [Messa E](#), [Fava M](#), [Giugliano E](#), [Rosso V](#), [Catalano R](#), [Merante S](#), [Nicoli P](#), [Rondoni M](#), [Ottaviani E](#), [Soverini S](#), [Tiribelli M](#), [Pane F](#), [Baccarani M](#), [Saglio G](#). WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. *Leukemia* 21(7):1442-50, 2007.

Impact Factor 8.634 Citation index 14

20. [Ottmann O](#), [Dombret H](#), [Martinelli G](#), [Simonsson B](#), [Guilhot F](#), [Larson RA](#), [Rege-Cambrin G](#), [Radich J](#), [Hochhaus A](#), [Apanovitch AM](#), [Gollerkeri A](#), [Coutre S](#). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. *Blood*, 110(7):2309-15, 2007.

Impact Factor 10.432 Citation index 188

21. [Soverini S](#), [Iacobucci I](#), [Baccarani M](#), [Martinelli G](#). Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. *Haematologica*, 92(4):437-9, 2007.

Impact Factor 5.032 Citation index 30

22. [Follo MY](#), [Mongiorgi S](#), [Bosi C](#), [Cappellini A](#), [Finelli C](#), [Chiarini F](#), [Papa V](#), [Libra M](#), [Martinelli G](#), [Cocco L](#), [Martelli AM](#). The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. *Cancer Res.*, 67(9):4287-94, 2007.

Impact Factor 7.514 Citation index 58

23. [Follo MY](#), [Finelli C](#), [Bosi C](#), [Martinelli G](#), [Mongiorgi S](#), [Baccarani M](#), [Manzoli L](#), [Blalock WL](#), [Martelli AM](#), [Cocco L](#). PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. *Leukemia*. 22(1):198-200, 2008.

Impact Factor 8.634 Citation index 29

24. [Vigna E](#), [Lucia E](#), [Gentile M](#), [Mazzone C](#), [Bisconte MG](#), [Gentile C](#), [Armentano A](#), [Ottaviani E](#), [Rondoni M](#), [Martinelli G](#), [Morabito F](#). PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. *Cancer Chemother Pharmacol*. 61(4):713-6, 2008.

Impact Factor 2.74 Citation index 4

25. [Cilloni D](#), [Martinelli G](#), [Messa F](#), [Baccarani M](#), [Saglio G](#). Nuclear factor kappaB as a target for new drug development in myeloid malignancies. *Haematologica*. 92(9):1224-9, 2007.

Impact Factor 5.032 Citation index 48

26. [Baccarani M](#), [Cilloni D](#), [Rondoni M](#), [Ottaviani E](#), [Messa F](#), [Merante S](#), [Tiribelli M](#), [Buccisano F](#), [Testoni N](#), [Gottardi E](#), [de Vivo A](#), [Giugliano E](#), [Iacobucci I](#), [Paolini S](#), [Soverini S](#), [Rosti G](#), [Rancati F](#), [Astolfi C](#), [Pane F](#), [Saglio G](#), [Martinelli G](#). The efficacy of imatinib mesylate in patients with FIP111-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. *Haematologica*. 92:1173-9, 2007.

Impact Factor 5.032 Citation index 115



27. [Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M, Pirrotta MT, Crupi R, Tozzuoli D, Trawinska MM, Defina M, Martinelli G, Lauria F](#). CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. *Leukemia*. 22(2):426-8, 2008.

Impact Factor 8.634 Citation index 13

28. [Piccaluga PP, Paolini S, Martinelli G](#). Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. *Cancer*. 110(6):1178-86, 2007.

Impact Factor 2.471 Citation index 41

29. Piccaluga PP, Rondoni M, Paolini S, Rosti G, **Martinelli G**, Baccarani M. Imatinib mesylate in the treatment of hematologic malignancies. *Expert Opin Biol Ther*. 7(10):1597-611, 2007.

Impact Factor 3.438 Citation index 15

30. Piccaluga PP, Malagola M, Rondoni M, Arpinati M, Paolini S, Candoni A, Fanin R, Messa E, Pirrotta MT, Lauria F, Visani G, Alberti D, Rancati F, Vinaccia V, Russo D, Saglio G, Baccarani M, **Martinelli G**. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. *Haematologica*. 92(12):1721-2, 2007.

Impact Factor 5.032 Citation index 115

31. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, **Martinelli G**, Radich JP, Zheng M, Shou Y, Kantarjian H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. *Blood*. 111(4):1834-9, 2008.

Impact Factor 10.432 Citation index 3

32. Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, **Martinelli G**. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. *Haematologica*. 92(9):1268-9, 2007.

Impact Factor 5.032 Citation index 35

33. [Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM](#). Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. *Leukemia*. 22(1):147-60, 2008.

Impact Factor 8.634 Citation index 88

34. [Derenzini E, Paolini S, Martinelli G, Campidelli C, Grazi GL, Calabrese C, Zinzani PL, Baccarani M](#). Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge. *Leuk Lymphoma* 49(1):159-62, 2008.

Impact Factor 1.939 Citation index 8

35. [Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G,](#)

[Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML.](#) Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. *J Clin Oncol.* 26(1):106-11, 2008.

Impact Factor 17.157 Citation index 36

36. **Martinelli G**, Rondoni M. Sindrome Ipereosinofila. *Seminari di Ematologia Oncologica – Sindromi rare*, 4(3): 201-11, 2007.

Impact Factor Citation index

37. [Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, Catalano R, Pautasso M, Panuzzo C, Nicoli P, Messa E, Morotti A, Iacobucci I, Martinelli G, Bracco E, Saglio G.](#) Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. *Leukemia* 22(6):1234-40, 2008.

Impact Factor 8.634 Citation index 35

38. Grafone T, Palmisano M, Nicci C, Martelli AM, Emanuela O, Storti S, Baccarani M, **Martinelli G**. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells. *Hematol Oncol.* 26(3):159-66, 2008.

Impact Factor 2.333 Citation index 2

39. Mancini M, Zuffa E, Veljkovic N, Brusa G, Corrado P, Corradi V, **Martinelli G**, Barbieri E, Santucci MA. IPO-trimethylation of histone H3-lysine(9) associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia. *Br J Haematol.* Jun;141(6):899-902, 2008.

Impact Factor 4.478 Citation index 15

40. [Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; on behalf of the GIMEMA Working Party on CML.](#) Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- $\alpha$ : 5-year outcome. *Haematologica.* 93(5):770-4, 2008.

Impact Factor 5.032 Citation index 39

41. [Piccaluga PP, Martinelli G, Isidori A, Malagola M, Rondoni M, Paolini S, Amabile M, Iacobucci I, Baccarani M, Visani G.](#) Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. *Leukemia* 22(8):1617-8, 2008.

Impact Factor 8.634 Citation index 6

42. [Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G, Blalock WL, Cocco L, Martelli AM.](#) PKR is activated in MDS patients and its subcellular localization depends on disease severity. *Leukemia* 22(12):2267-9, 2008.

Impact Factor 8.634 Citation index 15

43. **Martinelli G**, Iacobucci I, Paolini S, Ottaviani E. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. *Clin Adv Hematol Oncol.* 6(4):303-10, 2008.

Impact Factor Citation index

44. [Luatti S, Marzocchi G, Ottaviani E, Baldazzi C, Stacchini M, Gamberini C, Salmi F, Martinelli G, Baccarani M, Testoni N.](#) Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement: Clinical implications. *Leuk Res.* 32(12):1941-3, 2008.



Impact Factor 2.39 Citation index 1

45. [Cilloni D](#), [Messa F](#), [Arruga F](#), [Defilippi I](#), [Gottardi E](#), [Fava M](#), [Carturan S](#), [Catalano R](#), [Bracco E](#), [Messa E](#), [Nicoli P](#), [Diverio D](#), [Sanz MA](#), [Martinelli G](#), [Lo-Coco F](#), [Saglio G](#). Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. *Haematologica*. 93(6):921-4, 2008.

Impact Factor 5.032 Citation index 68

46. [Feldman EJ](#), [Cortes J](#), [Deangelo DJ](#), [Holyoake T](#), [Simonsson B](#), [O'Brien SG](#), [Reiffers J](#), [Turner AR](#), [Roboz GJ](#), [Lipton JH](#), [Maloisel F](#), [Colombat P](#), [Martinelli G](#), [Nielsen JL](#), [Petersdorf S](#), [Guilhot F](#), [Barker J](#), [Kirschmeier P](#), [Frank E](#), [Statkevich P](#), [Zhu Y](#), [Loechner S](#), [List A](#). On the use of Imafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. *Leukemia*. Sep;22(9):1707-11, 2008.

Impact Factor 8.634 Citation index 36

47. [Palmisano M](#), [Grafone T](#), [Renzulli M](#), [Ottaviani E](#), [Testoni N](#), [Paolini S](#), [Papayannidis C](#), [Baccarani M](#), [Martinelli G](#). Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. *Hematology*. 13(1):1-12, 2008.

Impact Factor 1.425 Citation index 2

48. [Soverini S](#), [Martinelli G](#), [Iacobucci I](#), [Baccarani M](#). Imatinib mesylate for the treatment of chronic myeloid leukemia. *Expert Rev Anticancer Ther*. 8(6):853-64, 2008.

Impact Factor 2.094 Citation index 27

49. [Fala F](#), [Blalock WL](#), [Tazzari P](#), [Cappellini A](#), [Chiarini F](#), [Martinelli G](#), [Tafari A](#), [McCubrey JA](#), [Cocco L](#), [Martelli AM](#). Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor, A443654, in T-Acute Lymphoblastic Leukemia. *Mol Pharmacol*. 74(3):884-95, 2008.

Impact Factor 4.711 Citation index 28

50. [Corrado P](#), [Mancini M](#), [Brusa G](#), [Petta S](#), [Martinelli G](#), [Barbieri E](#), [Santucci MA](#). Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia. *Leukemia*. Feb;23(2):405-6, 2009.

Impact Factor 8.296 Citation index 3

51. [Cortes J](#), [Kim DW](#), [Raffoux E](#), [Martinelli G](#), [Ritchie E](#), [Roy L](#), [Coutre S](#), [Corm S](#), [Hamerschlak N](#), [Tang JL](#), [Hochhaus A](#), [Khoury HJ](#), [Brümmendorf TH](#), [Michallet M](#), [Rege-Cambrin G](#), [Gambacorti-Passerini C](#), [Radich JP](#), [Ernst T](#), [Zhu C](#), [Van Tornout JM](#), [Talpaz M](#). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. *Leukemia*. 22(12):2176-83, 2008.

Impact Factor 8.296 Citation index 125

52. [Pantaleo MA](#), [Astolfi A](#), [Nannini M](#), [Paterini P](#), [Piazzi G](#), [Ercolani G](#), [Brandi G](#), [Martinelli G](#), [Pession A](#), [Pinna AD](#), [Biasco G](#). Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. *Br J Cancer*. 99(10):1729-34, 2008.

Impact Factor 5.569 Citation index 26

53. [Iacobucci I](#), [Lonetti A](#), [Cilloni D](#), [Messa F](#), [Ferrari A](#), [Zuntini R](#), [Ferrari S](#), [Ottaviani E](#), [Arruga F](#), [Paolini S](#), [Papayannidis C](#), [Piccaluga PP](#), [Soverini S](#), [Saglio G](#), [Pane F](#), [Baruzzi A](#), [Vignetti M](#), [Berton G](#), [Vitale A](#), [Chiaretti S](#), [Müschen M](#), [Foà R](#), [Baccarani M](#), [Martinelli G](#). Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute

lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. *Haematologica*. 93(12):1814-21, 2008.

Impact Factor 5.032 Citation index 20

54. [Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, \*\*Martinelli G\*\*, Baccarani M, Rosti G; on behalf of the GIMEMA Working Party on chronic myeloid leukemia.](#) Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. *Haematologica*. 93(12):1792-6, 2008.

Impact Factor 5.032 Citation index 51

55. Latagliata R, Breccia M, Fazi P, Iacobelli S, **Martinelli G**, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. *Br J Haematol*. 143(5):681-9, 2008.

Impact 4.478 Citation index 26

56. [Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Chiaretti S, Perini G, Foà R, Baccarani M, \*\*Martinelli G\*\*.](#) Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. *Blood*.;112(9):3847-55, 2008.

Impact Factor 10.432 Citation index 67

57. [Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, \*\*Martinelli G\*\*, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Fili C, Fanin R, Baccarani M, Russo D.](#) Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. *Eur J Haematol*.;81(5):354-63, 2008.

Impact Factor 2.544 Citation index 18

58. [Candoni A, \*\*Martinelli G\*\*, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.](#) Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. *Leuk Res*. 32(12):1800-8, 2008.

Impact Factor 2.39 Citation index 21

59. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, **Martinelli G**, Bontadini A, Cocco L, McCubrey JA, Martelli AM. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. *Cancer Res*. 68(22):9394-403, 2008.

Impact Factor 7.514 Citation index 65

60. Valentini CG, Rondoni M, Pogliani EM, Van Lint MT, Cattaneo C, Marbello L, Pulsoni A, Giona F, **Martinelli G**, Leone G, Pagano L. Mast cell leukemia: a report of ten cases. *Ann Hematol*. 87(6):505-8, 2008.

Impact Factor 2.454 Citation index 14

61. Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Baccarani M, Grimwade D, Preudhomme C, Apperley J, **Martinelli G**, Saglio G, Cross NC, Reiter A. The molecular anatomy of the FIP1L1-PDGFR $\alpha$  fusion gene. *Leukemia*. 23(2):271-8, 2009.

Impact Factor 8.296 Citation index 14

62. Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, **Martinelli G**, Leone G, Musto P. Advanced mast cell disease: an Italian Hematological Multicenter experience. *Int J Hematol*. 2008 Dec;88(5):483-8.

Impact Factor 1.283 Citation index 23

63. Follo MY, Finelli C, Clissa C, Mongiorgi S, Bosi C, **Martinelli G**, Baccarani M, Manzoli L, Martelli AM, Cocco L. Phosphoinositide-Phospholipase C  $\beta$ 1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia. *J Clin Oncol*. Feb 10;27(5):782-90, 2009.

Impact Factor 17.713 Citation index 38

64. **Martinelli G**, Soverini S, Iacobucci I, Baccarani M. Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. *Nat Clin Pract Oncol*. 6(2):68-9, 2009.

Impact Factor 8.075 Citation index 13

65. Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, **Martinelli G**, Mecucci C, Vignetti M, Tura S. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. *Haematologica*. 94(1):102-12, 2009.

Impact Factor 6.416 Citation index 14

66. Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, **Martinelli G**, Nagler A, Nielsen JL, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B. A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study. *Blood*. 113(19):4497-504, 2009.

Impact Factor 10.555 Citation index 120

67. Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M, **Martinelli G**, Baccarani M, Vianelli N. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. *Leuk Lymphoma*. Feb;50(2):247-53, 2009.

Impact Factor 2.392 Citation index 17

68. Mancini M, Veljkovic N, Corradi V, Zuffa E, Corrado P, Pagnotta E, **Martinelli G**, Barbieri E, Santucci MA. 14-3-3 Ligand Prevents Nuclear Import of C-ABL Protein in Chronic Myeloid Leukemia. *Traffic*. 10(6):637-47, 2009.

Impact Factor Citation index

69. Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, **Martinelli G**, Baccarani M, Rosti G. Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP. *Blood*. 113(15):3428-34, 2009.

Impact Factor 10.555 Citation index 49

70. Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, **Martinelli G**, Baccarani M, Rosti G. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. *Clin Cancer Res.*;15(3):1059-63, 2009.

Impact Factor 6.747 Citation index 19

71. Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, **Martinelli G**, Torelli G, Luppi M. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. *Br J Haematol*. 146(2):227-30, 2009.

Impact Factor 4.597 Citation index 4

72. Blalock WL, Grimaldi C, Fala F, Follo M, Horn S, Basecke J, **Martinelli G**, Cocco L, Martelli AM. PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. *J Cell Physiol*. 221(1):232-41, 2009.

Impact Factor 4.586 Citation index 11

73. Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R, Castagnetti F, Torelli GF, Usai S, Valle V, **Martinelli G**, Rosti G, Foà R, Baccarani M, Alimena G. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. *Leuk Res*. 34(2):143-7, 2010.

Impact Factor 2.555 Citation index 17

74. Harousseau JL, **Martinelli G**, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ. A randomized phase 3 study of tipifarnib compared to best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older. *Blood*. 114(6):1166-73, 2009.

Impact Factor 10.555 Citation index 5

75. Piccaluga PP, Sabattini E, Bacci F, Agostinelli C, Righi S, Salmi F, Testoni N, Paolini S, Castagnetti F, **Martinelli G**, Falini B, Pileri SA. [Cyttoplasmic mutated nucleophosmin \(NPM1\) in blast crisis of chronic myeloid leukaemia](#). *Leukemia*. 23(7):1370-1, 2009.

Impact Factor 8.296 Citation index 8

76. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA et al.; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. *Leukemia* 23(6):1054-61, 2009.

Impact Factor 8.296 Citation index 477

77. Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, **Martinelli G**, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G. Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. *Clin Cancer Res.* 15(15):5002-7, 2009.

Impact Factor 6.747 Citation index 68

78. Santucci MA, Mancini M, Corradi V, Iacobucci I, **Martinelli G**, Botta M, Schenone S. New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells. *Invest New Drugs* 28(6): 876-78, 2010.

Impact Factor 3.007 Citation index 6

79. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, **Martinelli G**, Heisterkamp N, Jumaa H, Müschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. *J Exp Med.* 206(8):1739-53, 2009.

Impact Factor 14.505 Citation index 72

80. Palandri F, Castagnetti F, Soverini S, Poerio A, Gugliotta G, Luatti S, Amabile M, **Martinelli G**, Rosti G, Baccarani M. Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. *Haematologica.* 94(12):1758-61, 2009.

Impact Factor 6.416 Citation index 17

81. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, **Martinelli G**. Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. *Blood.* 114(10):2168-71, 2009.

Impact Factor 10.555 Citation index 88

82. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, Castellani L, Bonetto C, Frattini F, Dama A, **Martinelli G**, Chilosi M, Senna G, Pizzolo G, Zanotti R. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. *J Allergy Clin Immunol.* Mar;123(3):680-6, 2009.

Impact Factor 9.165 Citation index 161

83. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Rege Cambrin G, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, **Martinelli G**, Alimena G, Pane F, Saglio G, Baccarani M. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. *Blood.* 114(24):4933-8, 2009.

Impact Factor 10.555 Citation index 131

84. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N, Chiarini F, Ramazzotti G, Baccarani M, Martelli AM, Manzoli L, **Martinelli G**, Cocco L. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. *Proc Natl Acad Sci U S A.* 106(39):16811-6, 2009.

Impact Factor 9.432 Citation index 60

85. Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, **Martinelli G**, Pane F, Rosti G, Baccarani M. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. *Blood*. 114(24):4939-43, 2009.

Impact Factor 10.555 Citation index 38

86. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, **Martinelli G**. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). *Blood* 114(10):2159-67, 2009.

Impact Factor 10.555 Citation index 113

87. **Martinelli G**, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foà R. IKZF1 (Ikaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. *J Clin Oncol*. 27(31):5202-7, 2009.

Impact Factor 17.793 Citation index 132

88. Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D, Soverini S, Paoloni F, Arruga F, Ottaviani E, Chiaretti S, Messina M, Vignetti M, Papayannidis C, Vitale A, Pane F, Piccaluga PP, Paolini S, Berton G, Baruzzi A, Saglio G, Baccarani M, Foà R, **Martinelli G**. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Leukemia* 24(1):66-73, 2010.

Impact Factor 8.966 Citation index 12

89. [Palandri F](#), [Castagnetti F](#), [Alimena G](#), [Testoni N](#), [Breccia M](#), [Luatti S](#), [Rege-Cambrin G](#), [Stagno F](#), [Specchia G](#), [Martino B](#), [Levato L](#), [Merante S](#), [Liberati AM](#), [Pane F](#), [Saglio G](#), [Alberti D](#), [Martinelli G](#), [Baccarani M](#), [Rosti G](#). The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. *Haematologica* 94(2):205-12, 2009.

Impact Factor 6.416 Citation index 40

90. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, **Martinelli G**, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. *Cancer Cell*. 8;16(3):232-45, 2009.

Impact Factor 25.288 Citation index 88

91. Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, **Martinelli G**, Baccarani M, Ferrari S, Manfredini R. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. *Blood*. 114(25):5191-200, 2009.

Impact Factor 10.555 Citation index 35



92. Papayannidis C, Derenzini E, Iacobucci I, Curti A, Paolini S, Cilloni D, Baccarani M, **Martinelli G**. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. *Am J Hematol*. 84(12):849-50, 2009.

Impact Factor 2.61 Citation index 7

93. Nicolini FE, Mauro MJ, **Martinelli G**, Kim DW, Soverini S, Muller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, Yagasaki F, Pearson JD, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman JM, Zhou W. Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation. *Blood*. 114(26):5271-8, 2009.

Impact Factor 10.432 Citation index 0

94. **Martinelli G**, Iacobucci I, Papayannidis C, Soverini S. New targets for Ph+ leukaemia therapy. *Best Pract Res Clin Haematol*. 22(3):445-54, 2009.

Impact Factor 3.134 Citation index 6

95. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, **Martinelli G**, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *J Clin Oncol*. 27(25):4204-10, 2009.

Impact Factor 17.793 Citation index 185

96. Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, Castagnetti F, Breccia M, Specchia G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. *Leuk Lymphoma* 50(1):114-8, 2009.

Impact Factor 2.397 Citation index 1

97. Mancini M, Petta S, **Martinelli G**, Barbieri E, Santucci MA. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. *J Cell Biochem*. 109(2):320-8, 2010.

Impact Factor 3.122 Citation index 17

98. Mancini M, Corradi V, Petta S, **Martinelli G**, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. *Leuk Res*. 34(5):641-8, 2010.

Impact Factor 2.555 Citation index 23

99. Baruzzi A, Iacobucci I, Soverini S, Lowell CA, **Martinelli G**, Berton G. c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration. *FEBS Lett*. 584(1):15-21, 2010.

Impact Factor 3.601 Citation index 18

100. Papayannidis C, Iacobucci I, Abbenante MC, Curti A, Parisi S, Paolini S, Testoni N, Baccarani M, Cilloni D, **Martinelli G**. Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. *Leuk Res*. 34(9):e246-7, 2010.

Impact Factor 2.555 Citation index 2

101. Palandri F, Castagnetti F, Iacobucci I, **Martinelli G**, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F,

Specchia G, Pane F, Saglio G, Rosti G, Baccarani M. The response to imatinib and interferon- $\alpha$  is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive Chronic Myeloid Leukemia patients in early chronic phase. *Haematologica*. 95(8):1415-9, 2010.

Impact Factor 6.532 Citation index 20

102.Rosti G, Castagnetti F, Gugliotta G, Palandri F, **Martinelli G**, Baccarani M. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. *Leuk Lymphoma*. (4):583-91, 2010.

Impact Factor 2.492 Citation index 18

103.Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, **Martinelli G**, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, McCubrey JA. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. *Leukemia*. 24(4):687-98, 2010.

Impact Factor 8.966 Citation index 17

104.Iacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT, Vignetti M, Cilloni D, Messa F, Guadagnuolo V, Paolini S, Elia L, Messina M, Vitale A, Meloni G, Soverini S, Pane F, Baccarani M, Foa' R, **Martinelli G**. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. *Haematologica* 95(10):1683-90, 2010.

Impact Factor 6.532 Citation index 16

105.Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, **Martinelli G**, Saglio G, Baccarani M, Rosti G. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. *J Clin Oncol*. 28(16):2748-54, 2010.

Impact Factor 18.97 Citation index 29

106.Della Peruta M, **Martinelli G**, Moratti E, Pintani D, Vezzalini M, Mafficini A, Grafone T, Iacobucci I, Soverini S, Murineddu M, Vinante F, Tecchio C, Piras G, Gabbas A, Monne M, Sorio C. Protein Tyrosine Phosphatase Receptor Type  $\gamma$  Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia. *Cancer Res*. 70(21):8896-906, 2010.

Impact Factor 8.234 Citation index 20

107.Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, **Martinelli G**, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. *Blood*. 116(17):3171-9, 2010.

Impact Factor 10.558 Citation index 112

108.Baldazzi C, Iacobucci I, Luatti S, Ottaviani E, Marzocchi G, Paolini S, Stacchini M, Papayannidis C, Gamberini C, **Martinelli G**, Baccarani M, Testoni N. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. *Leuk Res*. 34(10):e282-5, 2010.

Impact Factor 2.555 Citation index 14

109.Papayannidis C, Iacobucci I, Abbenante MC, Curti A, Paolini S, Parisi S, Baccarani M, **Martinelli G**. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. *Am J Hematol.* 85(8):608, 2010.

Impact Factor 3.576 Citation index 14

110.Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, **Martinelli G**. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. *Am J Hematol.* 85(3):164-70, 2010.

Impact Factor 3.576 Citation index 35

111.[Soverini S](#), [Vitale A](#), [Poerio A](#), [Gnani A](#), [Colarossi S](#), [Iacobucci I](#), [Cimino G](#), [Elia L](#), [Lonetti A](#), [Vignetti M](#), [Paolini S](#), [Meloni G](#), [di Maio V](#), [Papayannidis C](#), [Amabile M](#), [Guarini A](#), [Baccarani M](#), [Martinelli G](#), [Foa' R](#). Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. *Haematologica.* 96(4):552-7, 2011.

Impact Factor 6.424 Citation index 33

112.Soverini S, Score J, Iacobucci I, Poerio A, Lonetti A, Gnani A, Colarossi S, Ferrari A, Castagnetti F, Rosti G, Cervantes F, Hochhaus A, Delledonne M, Ferrarini A, Sazzini M, Luiselli D, Baccarani M, Cross NC, **Martinelli G**. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. *Leukemia.* 25(1):178-81, 2011.

Impact Factor 9.561 Citation index 11

113.Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G, Paolini S, **Martinelli G**, Martelli AM, Cocco L.Synergistic induction of PI-PLC $\beta$ 1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. *Leukemia.* 25(2):271-80, 2011.

Impact Factor 9.561 Citation index 21

114.[Kantarjian HM](#), [Giles FJ](#), [Bhalla KN](#), [Pinilla-Ibarz JA](#), [Larson RA](#), [Gattermann N](#), [Ottmann OG](#), [Hochhaus A](#), [Radich JP](#), [Saglio G](#), [Hughes TP](#), [Martinelli G](#), [Kim DW](#), [Shou Y](#), [Gallagher NJ](#), [Blakesley R](#), [Baccarani M](#), [Cortes J](#), [le Coutre PD](#). Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. *Blood.* 117(4):1141-5, 2011.

Impact Factor 9.898 Citation index 170

115.Soverini S, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M, **Martinelli G**.Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. *Leuk Res.* 35(11):1527-9, 2011.

Impact Factor 2.923 Citation index 3

116.Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, **Martinelli G**, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; for the GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. *Br J Haematol.* 154(5):564-8, 2011.

Impact Factor 5.3 Citation index 7

117.Kohlmann A, Klein HU, Weissmann S, Bresolin S, Chaplin T, Cuppens H, Haschke-Becher E, Garicochea B, Grossmann V, Hanczaruk B, Hebestreit K, Gabriel C, Iacobucci I, Jansen JH, Te Kronnie G, van de Locht L, **Martinelli G**, McGowan K, Schweiger MR, Timmermann B, Vandenberghe P, Young BD, Dugas M, Haferlach T. [The Interlaboratory RObustness of Next-generation sequencing \(IRON\) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.](#) *Leukemia*. 25(12):1840-8, 2011.

Impact factor 9.8 Citation index 69

118.Malagola M, Skert C, Vignetti M, Piciocchi A, **Martinelli G**, Alimena G, Mecucci C, Testoni N, Iacobucci I, Clavio M, Gobbi M, Candoni A, Damiani D, Bocchia M, Lauria F, Zaccaria A, Mazza P, Visani G, Peli A, Colombi C, Cancelli V, Mancini M, Fo R, Martelli M, Cantore N, Raimondo FD, Petrini M, de Fabritiis P, Fioritoni G, Nobile F, Fabbiano F, Specchia G, Baccarani M, Coco FL, Amadori S, Mandelli F, Russo D. A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. *Leuk Lymphoma*. 52(12):2329-35, 2011.

Impact factor 2.7 Citation index 0

119.Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccarani M, **Martinelli G**, Perini G. c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells. *Mol Cancer Res*. 9(8):1054-66, 2011.

Impact factor 4.9 Citation index 21

120.Brioli A, Parisi S, Iacobucci I, Cavo M, Papayannidis C, Anna Zannetti B, **Martinelli G**, Baccarani M. Patient with ataxia telangiectasia who developed acute myeloid leukemia. *Leuk Lymphoma*. 52(9):1818-20, 2011.

Impact factor 2.7 Citation index 3

121.Soverini S, Rosti G, Iacobucci I, Baccarani M, **Martinelli G**. Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? *Oncologist* 16(6):868-76, 2011

Impact factor 4.9 Citation index 15

122.Messina M, Chiaretti S, Iacobucci I, Tavolaro S, Lonetti A, Santangelo S, Elia L, Papayannidis C, Paoloni F, Vitale A, Guarini A, **Martinelli G**, Foà R. AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. *Br J Haematol*. 152(6):727-32, 2011.

Impact factor 5.3 Citation index 2

123.Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jäger R, Pieri L, Guglielmelli P, Iacobucci I, **Martinelli G**, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. *Blood*. 7;118(1):167-76, 2011.

Impact factor 10.2 Citation index 81

124.Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, **Martinelli G**, Bosi A, Vannucchi AM; on behalf of the AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative)

Investigators. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. *Blood*. 117(25):6923-6927, 2011.

Impact factor 10.2 Citation index 15

125. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, **Martinelli G**, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. *Blood*. 117(21):5591-9, 2011.

Impact factor 10.2 Citation index 54

126. Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, **Martinelli G**, Baccarani M, Rosti G, Testoni N; for the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. *Blood* 117(25):6793-6800, 2011.

Impact factor 10.2 Citation index 30

127. Iacobucci I, Sazzini M, Garagnani P, Ferrari A, Boattini A, Lonetti A, Papayannidis C, Mantovani V, Marasco E, Ottaviani E, Soverini S, Girelli D, Luiselli D, Vignetti M, Baccarani M, **Martinelli G**. A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. *Leuk Res*. 35(8):1052-9, 2011.

Impact factor 2.5 Citation index 27

128. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, TrabANELLI S, Giudice V, Urbani E, **Martinelli G**, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM. [Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients](#). *Blood*. 118(12):3273-9, 2011.

Impact factor 10.2 Citation index 125

129. Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propriis MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, **Martinelli G**, Baccarani M. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*. 118(25):6521-8, 2011.

Impact factor 10.2 Citation index 117

130. Nicolini FE, Basak GW, Soverini S, **Martinelli G**, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood*. 118(20):5697-700, 2011.

Impact factor 10.2 Citation index 25

131. Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, Deangelo DJ, Gambacorti-Passerini C, **Martinelli G**, Tefferi A. Chronic myeloid leukemia 2011: Successes,

challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. *Am J Hematol.* 86(9):811-9, 2011.

Impact factor Citation index

132. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, **Martinelli G**, Pane F. [SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.](#) *Blood.* 118(13):3634-44, 2011.

Impact factor 10.2 Citation index 22

133. Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, **Martinelli G**, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. [Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib \(AZD1152\) in patients with advanced acute myeloid leukemia.](#) *Blood.* 118(23):6030-6, 2011.

Impact factor Citation index

134. Waldron T, De Dominici M, Soliera AR, Audia A, Iacobucci I, Lonetti A, **Martinelli G**, Zhang Y, Martinez R, Hyslop T, Bender TP, Calabretta B. [c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.](#) *Leukemia.* 26(4):644-53, 2012.

Impact factor 9.8 Citation index 17

135. [Perbellini O](#), [Zamò A](#), [Colarossi S](#), [Zampieri F](#), [Zoppi F](#), [Bonadonna P](#), [Scheda D](#), [Artuso A](#), **Martinelli G**, [Chilosi M](#), [Pizzolo G](#), [Zanotti R](#). Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders. *Cytometry B Clin Cytom.* 80(6):362-8, 2011.

Impact factor 2.3 Citation index 9

136. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, **Martinelli G**. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood.* 118(5):1208-15, 2011.

Impact factor 9.898 Citation index 202

137. [Iacobucci I](#), [Papayannidis C](#), [Lonetti A](#), [Ferrari A](#), [Baccarani M](#), **Martinelli G**. Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. *Curr Hematol Malig Rep.* 7(2):133-43, 2012.

Impact factor 1.9 Citation index 19

138. [Follo MY](#), [Mongiorgi S](#), [Clissa C](#), [Paolini S](#), **Martinelli G**, [Martelli AM](#), [Fioravanti G](#), [Manzoli L](#), [Finelli C](#), [Cocco L](#). Activation of nuclear inositol signalling pathways during erythropoietin therapy in low-risk MDS patients. *Leukemia* 26(12):2474-82, 2012.

Impact factor 9.8 Citation index 10

139. Leo E, Mancini M, Aluigi M, Castagnetti F, **Martinelli G**, Barbieri E, Santucci MA. [DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L1 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia.](#) *Br J Haematol.* 159(3):373-6, 2012.

Impact factor 5.3 Citation index 7



140.Soverini S, **Martinelli G**, Rosti G, Iacobucci I, Baccarani M. [Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.](#) *Pharmacogenomics* 13(11):1271-84, 2012.

Impact factor 3.857 Citation index 13

141.Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, Foà R, Baccarani M, Müschen M, Perini G, **Martinelli G**. [IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia.](#) *PLoS One* 2012;7(7):e40934.

Impact factor 3.5 Citation index 25

142.Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Xumerle L, Ferrari A, Papayannidis C, Malerba G, Luiselli D, Boattini A, Garagnani P, Vitale A, Soverini S, Pane F, Baccarani M, Delledonne M, **Martinelli G**. [Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.](#) *Blood Cancer J.* 2(3):e61, 2012.

Impact factor 4 Citation index 3

143.Riva G, Luppi M, Quadrelli C, Barozzi P, Basso S, Vallerini D, Zanetti E, Morselli M, Forghieri F, Maccaferri M, Paolini A, Del Giovane C, D'Amico R, Marasca R, Narni F, Iacobucci I, **Martinelli G**, Baccarani M, Comoli P, Potenza L. [BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph\(+\) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy.](#) *Blood Cancer J.* 1(7):e30, 2011.

Impact factor 4 Citation index 3

144.Abate F, Acquaviva A, Paciello G, Foti C, Ficarra E, Ferrarini A, Delledonne M, Iacobucci I, Soverini S, **Martinelli G**, Macii E. [Bellerophon: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model.](#) *Bioinformatics.* 28(16):2114-21, 2012.

Impact factor 7.6 Citation index 15

145.Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, **Martinelli G**, Rosti G, Baccarani M, Testoni N; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML. [Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.](#) *Blood* 120(4):761-767, 2012.

Impact factor 10.2 Citation index 35

146.Impera L, Daniele G, Marra L, Baldazzi C, Iacobucci I, **Martinelli G**, Testoni N, Storlazzi CT. [A novel t\(2;10\)\(q31;p12\) balanced translocation in acute myeloid leukemia.](#) *Hematol Rep.* 4(4):e27, 2012.

Impact factor Citation index

147.Branford S, [Kim DW](#), [Soverini S](#), [Haque A](#), [Shou Y](#), [Woodman RC](#), [Kantarjian HM](#), [Martinelli G](#), [Radich JP](#), [Saglio G](#), [Hochhaus A](#), [Hughes TP](#), [Müller MC](#). Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *J Clin Oncol.* 10;30(35):4323-9, 2012.

Impact factor 18 Citation index 46

148. Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, **Martinelli G**, Amadori S, McCubrey JA, Martelli AM. [A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.](#) *Oncotarget*. 3(12):1615-28, 2012.

Impact factor 5.4 Citation index 38

149. Jabbour E, [le Coutre PD](#), [Cortes J](#), [Giles F](#), [Bhalla KN](#), [Pinilla-Ibarz J](#), [Larson RA](#), [Gattermann N](#), [Ottmann OG](#), [Hochhaus A](#), [Hughes TP](#), [Saglio G](#), [Radich JP](#), [Kim DW](#), **Martinelli G**, [Reynolds J](#), [Woodman RC](#), [Baccarani M](#), [Kantarjian HM](#). Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. *Leukemia*. 27(4):907-13, 2013.

Impact factor 9.8 Citation index 12

150. [Mijatovic V](#), [Iacobucci I](#), [Sazzini M](#), [Xumerle L](#), [Mori A](#), [Pignatti PF](#), **Martinelli G**, [Malerba G](#). Imputation reliability on DNA biallelic markers for drug metabolism studies. *BMC Bioinformatics*. 13 Suppl 14:S7, 2012.

Impact factor 3.4 Citation index 2

151. Van Etten [RA](#), [Mauro M](#), [Radich JP](#), [Goldman JM](#), [Saglio G](#), [Jamieson C](#), [Soverini S](#), [Gambacorti-Passerini C](#), [Hehlmann R](#), **Martinelli G**, [Perrotti D](#), [Scadden DT](#), [Skorski T](#), [Tefferi A](#), [Mughal TI](#). Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leuk Lymphoma* 54(6):1151-8, 2013.

Impact factor 2.6 Citation index 6

152. Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, **Martinelli G**, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellicchia M, Reed JC, Jamieson CH. [A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition.](#) *Cell Stem Cell*. 12(3):316-28, 2013.

Impact factor 2.7 Citation index 6

153. Polverelli N, Palandri F, Iacobucci I, Catani L, **Martinelli G**, Vianelli N. [Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.](#) *Br J Haematol*. 161(1):142-4, 2013.

Impact factor 5.3 Citation index 7

154. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, **Martinelli G**, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. *Leukemia*. 27(1):107-12, 2013.

Impact factor 9.8 Citation index 77

155. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, **Martinelli G**. [Association between imatinib transporters](#)

[and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.](#) *Haematologica* 98(2):193-200, 2013.

Impact factor 5.8 Citation index 37

156. Arpinati M, Tolomelli G, Bochicchio MT, Castagnetti F, Amabile M, Bandini G, Bonifazi F, Stanzani M, Rosti G, **Martinelli G**, Baccarani M. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. *Biol Blood Marrow Transplant.* 19(5):735-40, 2013.

Impact factor 3.9 Citation index 11

157. Kantarjian HM, **Martinelli G**, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A; on behalf of the SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of dasatinib (BMS-215486) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. *Cancer.* 119(14):2611-9, 2013.

Impact factor 5.4 Citation index 33

158. Stein AM, **Martinelli G**, [Hughes TP](#), [Müller MC](#), [Beppu L](#), [Gottardi E](#), [Branford S](#), [Soverini S](#), [Woodman RC](#), [Hochhaus A](#), [Kim DW](#), [Saglio G](#), [Radich JP](#). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer.* Apr13(1):173, 2013.

Impact factor 3.6 Citation index 5

159. Nicolini FE, Ibrahim AR, Soverini S, **Martinelli G**, Müller MC, Hochhaus A, Dufva IH, Kim DW, Cortes J, Mauro MJ, Chuah C, Labussière H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FO, Marin D, Etienne G. [The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.](#) *Haematologica* 98(10): 1510-6, 2013.

Impact factor 5.8 Citation index 14

160. Terragna C, Renzulli M, Remondini D, Tagliafico E, Di Raimondo F, Patriarca F, **Martinelli G**, Roncaglia E, Masini L, Tosi P, Zamagni E, Tacchetti P, Ledda A, Brioli A, Angelucci E, Testoni N, Marzocchi G, Galièni P, Gozzetti A, Martello M, Dico F, Mancuso K, Cavo M. [Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.](#) *Ann Hematol.* 92(9):1271-80, 2013.

Impact factor 2.7 Citation index 3

161. Fili C, Malagola M, Follo MY, Finelli C, Iacobucci I, **Martinelli G**, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D. [Lanza. Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1-Risk Myelodysplastic Syndromes.](#) *Clin Cancer Res.* 19(12):3297-3308, 2013.

Impact factor Citation index

162. Russo D, **Martinelli G**, Malagola M, Skert C, Soverini S, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregnò P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Fava C, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M. [Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.](#) *Blood.* 121(26):5138-44, 2013.

Impact factor 10.2 Citation index 12

163.Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, **Martinelli G**. [Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain](#). *Blood* 122(9):1634-48, 2013.

Impact factor 11.841 Citation index 66

164.Experts in Chronic Myeloid Leukemia.[The price of drugs for chronic myeloid leukemia \(CML\) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts](#). *Blood*. 121(22):4439-42, 2013.

Impact factor 10.2 Citation index 139

165.Sartor C, Papayannidis C, Chiara Abbenante M, Iacobucci I, Broccoli A, Venturi C, Testoni N, Ferrari A, **Martinelli G**. Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome. *Hematol Rep*. 5(2):26-7, 2013.

Impact factor Citation index

166.Sartor C, Papayannidis C, Chiara Abbenante M, Curti A, Polverelli N, Ottaviani E, Iacobucci I, Guadagnuolo V, **Martinelli G**. A case report of acute myeloid leukemia and neurofibromatosis 1. *Hematol Rep*. 5(2):28-9, 2013

Impact factor Citation index

167.Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, **Martinelli G**, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saúbele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*. 122(6):872-84, 2013.

Impact factor 10.2 Citation index 537

168.Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, **Martinelli G**, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. *Leuk Res*. 37(9):1100-6, 2013.

Impact factor 2.5 Citation index 9

169.Mancini M, Leo E, Takemaru K, Campi V, Borsi E, Castagnetti F, Gugliotta G, Santucci MA, **Martinelli G**. Chibby drives  $\beta$  catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells. *Cell Signal*. 25(9):1820-7, 2013.

Impact factor 4.1 Citation index 5

170.Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, **Martinelli G**, Rambaldi A, Bosi A. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. *Transfusion* 54(2):331-9, 2014.

Impact factor 3.0 Citation index 16

171.Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, **Martinelli G**, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, Pelicci PG. [Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups](#). *Blood Cancer J.* 4:e195, 2014.

Impact factor 4.0 Citation index 1

172.Riva G, Luppi M, Lagreca I, Barozzi P, Quadrelli C, Vallerini D, Zanetti E, Basso S, Forghieri F, Morselli M, Maccaferri M, Paolini A, Fantuzzi V, Messerotti A, Maffei R, Iacobucci I, **Martinelli G**, Marasca R, Narni F, Comoli P, Potenza L. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following Imatinib withdrawal in an elderly patient with Philadelphia-positive ALL. *Br J Haematol.* 164(2):299-302, 2014.

Impact factor 5.3 Citation index 5

173.Iacobucci I, Lonetti A, Papayannidis C, **Martinelli G**. Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia. *Curr Cancer Drug Targets* 13(7):791-810, 2013.

Impact factor 3.4 Citation index 2

174.Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, **Martinelli G**. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. *Pharmacogenomics J* 13(4):335-41, 2013.

Impact factor 3.6 Citation index 6

175.Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, **Martinelli G**, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D. Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. *Am J Hematol.* 89(2):119-24, 2014.

Impact factor 4.0 Citation index 6

176.[Quintarelli C](#), [De Angelis B](#), [Errichiello S](#), [Caruso S](#), [Esposito N](#), [Colavita I](#), [Raia M](#), [Pagliuca S](#), [Pugliese N](#), [Risitano AM](#), [Picardi M](#), [Luciano L](#), [Saglio G](#), **Martinelli G**, [Pane F](#). Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. *Leuk Res.* 38(2):236-42, 2014.

Impact factor 2.5 Citation index 8

177.Leo E, Mancini M, Aluigi M, Luatti S, Castagnetti F, Testoni N, Soverini S, Santucci MA, **Martinelli G**. [BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia](#). *PLoS One* 8(12):e81425, 2013.

Impact factor 3.5 Citation index 4

178.Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, **Martinelli G**, Müller MC, Radich JP, Shah NP. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. *Leuk Res.* 38(1):10-20, 2014.

Impact factor 2.5 Citation index 26



179.Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, **Martinelli G**. [Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement](#). *Cancer* 120(7):1002-9, 2014. Impact factor 5.4 Citation index 29

180.Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, **Martinelli G**, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C. [Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors](#). *Blood* 123(9):1309-18, 2014. Impact factor 10.2 Citation index 0

181.Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G, Baracca A, Sgarbi G, Pasquinelli G, Valente S, Zamagni E, Tacchetti P, **Martinelli G**, Cavo M. [Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma](#). *Oncotarget*. 5(7):1779-92, 2014. Impact factor 5.4 Citation index 11

182.**Martinelli G**, Sartor C, Papayannidis C, Iacobucci I, Paolini S, Clissa C, Ottaviani E, Finelli C. Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering". *Recenti Prog Med*.105(3):118-22, 2014. Impact factor Citation index

183.Iacobucci I, Lonetti A, Venturi C, Ferrari A, Papayannidis C, Ottaviani E, Abbenante MC, Paolini S, Bresciani P, Potenza L, Parisi S, Cattina F, Soverini S, Russo D, Luppi M, **Martinelli G**. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. *Leuk Res*. 38(5):581-5, 2014. Impact factor 2.606 Citation index 8

184.Soverini S, Rosti G, Baccarani M, **Martinelli G**. [Molecular monitoring](#). *Curr Hematol Malig Rep*. 9(1):1-8, 2014. Impact factor Citation index

185.Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, **Martinelli G**, Papayannidis C, Nagler A, Giles FJ. [A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia](#). *Blood Cancer J*. 4:e238, 2014. Impact factor 4.07 Citation index 16

186.Papayannidis C, Volpato F, Iacobucci I, Abbenante MC, Sartor C, **Martinelli G**. Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule. *Hematol Rep*. 30;6(3):5565, 2014. Impact factor Citation index

187.Rizzari C, Putti MC, Colombini A, Casagrande S, Ferrari GM, Papayannidis C, Iacobucci I, Abbenante MC<sup>3</sup>, Sartor C, **Martinelli G**<sup>3</sup>. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. *Hematol Rep*. 6(3):5554, 2014.



Impact factor Citation index

188. Mancini M, Leo E, Campi V, Castagnetti F, Zazzeroni L, Gugliotta G, Santucci MA, **Martinelli G**. A calpain-cleaved fragment of  $\beta$ -catenin promotes BCRA1+ cell survival evoked by autophagy induction in response to imatinib. *Cell Signal*. 26(8):1690-7, 2014.

Impact factor 4.1 Citation index 5

189. Fazio G, Daniele G, Cazzaniga V, Impera L, Severgnini M, Iacobucci I, Galbiati M, Leszl A, Cifola I, De Bellis G, Bresciani P, **Martinelli G**, Basso G, Biondi A, Storlazzi CT, Cazzaniga G. Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. *Haematologica* 100(1):e14-7, 2015.

Impact factor 6.6 Citation index 5

190. [Derenzini E](#), [Agostinelli C](#), [Imbrogno E](#), [Iacobucci I](#), [Casadei B](#), [Brighenti E](#), [Righi S](#), [Fuligni F](#), [Ghelli Luserna Di Rorà A](#), [Ferrari A](#), [Martinelli G](#), [Pileri S](#), [Zinzani PL](#). Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. *Oncotarget* 6(9):6553-69, 2015.

Impact factor 5.0 Citation index 6

191. Amabile G, Di Ruscio A, Müller F, Welner RS, Yang H, Ebralidze AK, Zhang H, Levantini E, Qi L, **Martinelli G**, Brummelkamp T, Le Beau MM, Figueroa ME, Bock C, Tenen DG. Dissecting the role of aberrant DNA methylation in human leukaemia. *Nat Commun*. 6:7091, 2015.

Impact factor 11.3 Citation index 14

192. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, **Martinelli G**, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood*. 126(3):291-9, 2015.

Impact factor 11.8 Citation index 114

193. Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, Pontes LL, Ye M, Levantini E, Di Ruscio A, **Martinelli G**, Tenen DG. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. *Cancer Cell*. 27(5):671-81, 2015.

Impact factor 23.2 Citation index 12

194. Forghieri F, Paolini A, Morselli M, Bigliardi S, Bonacorsi G, Leonardi G, Coluccio V, Maccaferri M, Fantuzzi V, Faglioni L, Colaci E, Soci F, Nasillo V, Messerotti A, Arletti L, Pioli V, Zucchini P, Quadrelli C, Corradini G, Giacobbi F, Vallerini D, Riva G, Barozzi P, Lagreca I, Marasca R, Narni F, Mecucci C, Ottaviani E, **Martinelli G**, Falini B, Luppi M, Potenza L. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. *Leuk. Lymphoma* 12:1-5, 2015.

Impact factor 3.09 Citation index 1

195. Savini P, Rondoni M, Poletti G, Lanzi A, Quercia O, Soverini S, De Benedittis C, Musardo G, **Martinelli G**, Stefanini GF. Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant). *Case Rep Hematol*. 2015:737302, 2015.

Impact factor Citation index

196.Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, **Martinelli G**, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, Pelicci PG. The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. *Mol Cancer Ther.* 14(4):889-98, 2015.

Impact factor 5.5 Citation index 5

197.Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, **Martinelli G**, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia* 29(5):999-1003, 2015.

Impact factor 12.1 Citation index 53

198.De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Garcia-Montero A, Bonifacio M, Sartori M, Aprili F, Caruso B, Paviati E, Carli G, Perbellini O, Zamò A, Bonadonna P, Pizzolo G, Guidi G, **Martinelli G**, Soverini S. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. *Leuk Res.* 39(3):273-8, 2015.

Impact factor 2.6 Citation index 1

199.Bodini M, Ronchini C, Giacò L, Russo A, Melloni GE, Luzi L, Sardella D, Volorio S, Hasan SK, Ottone T, Lavorgna S, Lo-Coco F, Candoni A, Fanin R, Toffoletti E, Iacobucci I, **Martinelli G**, Cignetti A, Tarella C, Bernard L, Pelicci PG, Riva L. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. *Blood* 125(4):600-5, 2015.

Impact factor 11.8 Citation index 5

200.Leo E, Mancini M, Castagnetti F, Gugliotta G, Santucci MA, **Martinelli G**. DNA methyltransferase 1 drives transcriptional down-modulation of  $\beta$  catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. *J Cell Biochem.* 116(4):589-97, 2015.

Impact factor 3.4 Citation index 0

201.Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, **Martinelli G**, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. *J Cancer Res Clin Oncol.* 141(5):887-99, 2015.

Impact factor 3.1 Citation index 8

202.Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pugno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, **Martinelli G**, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Ann Oncol.* 26(1):185-92, 2015.

Impact factor 9.2 Citation index 12

203.Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, **Martinelli G**, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in

follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. *Am J Hematol.* 90(1):56-61, 2015.

Impact factor 5 Citation index 3

204.Fazio G, Daniele G, Cazzaniga V, Impera L, Severgnini M, Iacobucci I, Galbiati M, Leszl A, Cifola I, De Bellis G, Bresciani P, **Martinelli G**, Basso G, Biondi A, Storlazzi CT, Cazzaniga G. Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. *Haematologica* 100(1):e14-7, 2015.

Impact factor 6.6 Citation index 5

205.White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni , Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, **Martinelli G**, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. *Leukemia* 29(2):369-76, 2015.

Impact factor 12.1 Citation index 17

206.Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, **Martinelli G**, Saglio G, Baccarani M, Rosti G. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica* 100(9):1146-50, 2015.

Impact factor 6.6 Citation index 11

207.Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, **Martinelli G**, Pane F, Saglio G, Rosti G, Baccarani M. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia.* 29(9):1823-31, 2015.

Impact factor 12.1 Citation index 21

208.Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, **Martinelli G**, Catani L, Baccarani M, Vianelli N. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. *Leukemia* 29(6):1344-9, 2015.

Impact factor 12.1 Citation index 14

209.Mosna F, Papayannidis C, **Martinelli G**, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. *Am J Hematol.* 90(6):515-23, 2015.

Impact factor 5 Citation index 8

210. Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, Pontes LL, Ye M, Levantini E, Di Ruscio A, **Martinelli G**, Tenen DG. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. *Cancer Cell*. 27(5):671-81, 2015.

Impact factor 23.2 Citation index 12

211. Derenzini E, Iacobucci I, Agostinelli C, Imbrogno E, Storlazzi CT, L Abbate A, Casadei B, Ferrari A, Di Rora AG, **Martinelli G**, Pileri S, Zinzani PL. Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. *Exp Hematol Oncol*. 27;4:24, 2015.

Impact factor Citation index

212. Soverini S, de Benedittis C, Mancini M, **Martinelli G**. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. Suppl:S120-8, 2015.

Impact factor 2.3 Citation index 14

213. Trino S, De Luca L, Simeon V, Laurenzana I, Morano A, Caivano A, La Rocca F, Pietrantuono G, Bianchino G, Grieco V, Signorino E, Fragasso A, Bochicchio MT, Venturi C, Rosti G, **Martinelli G**, Del Vecchio L, Cilloni D, Musto P. Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. *Tumour Biol*. 37(1):217-25, 2016.

Impact factor 2.9 Citation index 0

214. Musuraca G, De Matteis S, Napolitano R, Papayannidis C, Guadagnuolo V, Fabbri F, Cangini D, Ceccolini M, Giannini MB, Lucchesi A, Ronconi S, Mariotti P, Savini P, Tani M, Fattori PP, Guidoboni M, **Martinelli G**, Zoli W, Amadori D, Carloni S. IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. *J Transl Med*. 13:229, 2015.

Impact factor 3.6 Citation index 4

215. Mancini M, Leo E, Takemaru K, Campi V, Castagnetti F, Soverini S, De Benedittis C, Rosti G, Cavo M, Santucci MA, **Martinelli G**. 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of  $\beta$ -catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. *PLoS One* 10(7):e0131074, 2015.

Impact factor 3.05 Citation index 2

216. Voso MT, Fabiani E, Zang Z, Fianchi L, Falconi G, Padella A, Martini M, Li Zhang S, Santangelo R, Larocca LM, Criscuolo M, La Brocca A, Cutcutache I, Rozen S, Simonetti G, Manfrini M, **Martinelli G**, Hohaus S, Leone G, Tan P, Tenen DG. Fanconi anemia gene variants in therapy-related myeloid neoplasms. *Blood Cancer J*. 5:e323, 2015.

Impact factor 4.4 Citation index 5

217. Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, **Martinelli G**. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. *J Hematol Oncol*. 8(1):125, 2015.

Impact factor 6.2 Citation index 4

218. Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, **Martinelli G**, Palumbo A, Cavo

M. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). *Oncotarget*. 2016 Nov 9.

Impact factor 5 Citation index 2

219.Zuffa E, Franchini E, Papayannidis C, Baldazzi C, Simonetti G, Testoni N, Abbenante MC, Paolini S, Sartor C, Parisi S, Marconi G, Cattina F, Bochicchio MT, Venturi C, Ottaviani E, Cavo M, **Martinelli G**. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. *Oncotarget*. 6(31):31284-94, 2015. Impact factor 5.008 Citation index 5

220.**Martinelli G**, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C. Treatment with PF-04449913, an oral smoothed antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. *Lancet Haematol*. 2(8):e339-46, 2015. Impact factor 4.889 Citation index 13

221.Soverini S, **Martinelli G**. Interferon in CML: back to the past, or towards the future? *Lancet Haematol*. 2(1):e8-9, 2015.

Impact factor 4.8 Citation index 0

222.Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D'Emilio A, Santini V, Girasoli M, Lorenzo RD, Bernardi S, Palma AD, Cesana BM, Soverini S, **Martinelli G**, Rosti G, Baccarani M. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. *Blood Cancer J*. 18:5:e347, 2015. Impact factor 4.4 Citation index 0

223.Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Falcone AP, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, **Martinelli G**, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. *Am J Hematol* 91(6):617-22, 2016.

Impact Factor 4.003 Citation index 5

224.Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, **Martinelli G**, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. *J Natl Cancer Inst* 4;108(7), 2016.

Impact Factor 11.370 Citation index 5

225.Reis B, Jukofsky L, Chen G, **Martinelli G**, Zhong H, So V, Dickinson MJ, Drummond M, Assouline S, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE. Acute myeloid leukemia patient clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. *Haematologica* 101(5):e185-8, 2016.

Impact Factor 5,814 Citation index 5

226.Soverini S, De Benedittis C, Machova Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, **Martinelli G**. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget* 19;7(16):21982-90, 2016.

Impact Factor 5.008 Citation index 1

227.Soverini S, De Benedittis C, Mancini M, **Martinelli G**. Present and future of molecular monitoring in chronic myeloid leukaemia. *Br J Haematol* 173(3):337-49, 2016.

Impact Factor 5.812 Citation index 3

228.Trino S, Iacobucci I, Erriquez D, Laurenzana I, Luca L, Ferrari A, Rorà AG, Papayannidis C, Derenzini E, Simonetti G, Lonetti A, Venturi C, Cattina F, Ottaviani E, Abbenante MC, Russo D, Perini G, Musto P, **Martinelli G**. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. *Oncotarget* 15;7(11):12951-61, 2016.

Impact Factor 5.008 Citation index 4

229.Nicolini FE, Basak GW, Kim DW, Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. *Oncotarget*. 31;7(22):32532-42, 2016.

Impact Factor 5.008 Citation index 2

230.Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, **Martinelli G**, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. *Haematologica* 101(10):1200-1207, 2016.

Impact Factor 5.8140 Citation index 1

231.Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, **Martinelli G**, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. *Haematologica* 101(12):1524-15, 2016.

Impact Factor 5.8140 Citation index 5

232.Goekbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, **Martinelli G**, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. *Blood Cancer J* 23;6(9):e4, 2016.

Impact Factor 4.411 Citation index 0

233.Ghelli Luserna Di Rorà A, Iacobucci I, Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, **Martinelli G**. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. *Oncotarget* 16;7(33):53377-53391, 2016.



Impact Factor 5.008 Citation index 3

234. Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, Scalzulli PR, Rumi E, Dragani A, Martinelli V, Santoro C, Randi ML, Tagariello G, Candoni A, Cattaneo D, Ricco A, Palmieri R, Liberati MA, Langella M, Rago A, Bergamaschi M, Monari P, Miglio R, Santoro U, Cacciola R, Rupoli S, Mastrullo L, Musto P, Mazzucconi MG, Vignetti M, Cortelezzi A, Vianelli N, Martino B, De Stefano V, Passamonti F, Vannucchi AM; Registro Italiano Trombocitemie RIT. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. *Leuk Res* 46:18-25, 2016.

Impact Factor 2.606 Citation index 1

235. Kantarjian HM, DeAngelo DJ, Stelljes M, **Martinelli G**, Liedtke M, Stock W, Goekbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. *N Engl J Med* 25;375(8):740-53, 2016.

Impact Factor 59.558 Citation index 33

236. Martello M, Remondini D, Borsi E, Santacroce B, Procacci M, Pezzi A, Dico FA, **Martinelli G**, Zamagni E, Tacchetti P, Pantani L, Testoni N, Marzocchi G, Rocchi S, Zannetti BA, Mancuso K, Cavo M, Terragna C. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. *Leukemia* 30(9):1869-76, 2016.

Impact Factor 12.104 Citation index 0

237. Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfý F, Salerno R, Fanelli T, Gesullo F, Corbizi Fattori G, Bonifacio M, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, **Martinelli G**, Triggiani M, Merante S, Vannucchi AM, Zanotti R. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *Am J Hematol* 91(7):692-9, 2016.

Impact Factor 5 Citation index 4

238. Sollazzo D, Forte D, Polverelli N, Romano M, Perricone M, Rossi L, Ottaviani E, Luatti S, **Martinelli G**, Vianelli N, Cavo M, Palandri F, Catani L. Crucial factors of the inflammatory microenvironment (IL-1 $\beta$ /TNF- $\alpha$ /TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. *Oncotarget* 12;7(28):43974-43988, 2016.

Impact Factor 5.008 Citation index 2

239. Soverini S, Baccarani M, **Martinelli G** Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. *Lancet Haematol* 3(12):e554-e555, 2016.

Impact Factor 0.0000 Citation index 0

240. Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, **Martinelli G**. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer* 2;16:572, 2016.

Impact Factor 3.3620 Citation index 0

241. Tenti E, Papayannidis C, Marconi G, Parisi S, Simonetti G, Paolini S, Sartor C, Ottaviani E, Testoni N, **Martinelli G**. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. *Expert Opin Pharmacother* 17(18):2479-2486, 2016.

Impact Factor 3.543 Citation index 0

242. Trino S, De Luca L, Laurenzana I, Caivano A, Del Vecchio L, **Martinelli G**, Musto P. P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. *Front Pharmacol* 16;7:491, 2016.

Impact Factor 4.418 Citation index 0

243. do Valle ÍF, Giampieri E, Simonetti G, Padella A, Manfrini M, Ferrari A, Papayannidis C, Zironi I, Garonzi M, Bernardi S, Delledonne M, **Martinelli G**, Remondini D, Castellani G. Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. *BMC Bioinformatics* 8;17(Suppl 12):341, 2016.

Impact Factor 2.435 Citation index 0

244. N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, **Martinelli G**, Lewis RE, Vianelli N, Cavo M, Palandri F. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. *Am J Hematol* 92(1):37-41, 2017.

Impact Factor 5.000 Citation index 0

245. Andreeff M, Kelly KR, Yee KW, Assouline SE, Strair R, Popplewell L, Bowen D, **Martinelli G**, Drummond MW, Vyas P, Kirschbaum MH, Padmanabhan Iyer S, Ruvolo VR, Noguera-Gonzalez GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. *Clin Cancer Res.* 22(4):868-76, 2016.

Impact factor 8.7 Citation index 21

246. Lonetti A, Fontana MC, **Martinelli G**, Iacobucci I. Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies. *Methods Mol Biol.* 2016;1368:143-59, 2016.

Impact factor Citation index

247. Baldazzi C, Luatti S, Paolini S, Papayannidis C, Marzocchi G, Ameli G, **Martinelli G**, Cavo M, Testoni N. FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. *Am J Hematol.* 91(3):E14-6, 2016.

Impact factor 5 Citation index 2

248. Di Liddo R, Bridi D, Gottardi M, De Angeli S, Grandi C, Tasso A, Bertalot T, **Martinelli G**, Gherlinzoni F, Conconi MT. [Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells.](#) *Int J Oncol.* 2016 Feb 2. doi: 10.3892/ijo.2016.3370. [Epub ahead of print]

Impact factor 3 Citation index 0

249. Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, Ameli G, Bardi MA, Bonaldi L, Paolini R, Gurrieri C, Rigolin GM, Cuneo A, **Martinelli G**, Cavo M, Testoni N. [Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in](#)

[myeloid malignancies with various 3q abnormalities](#). *Genes Chromosomes Cancer*. 55(4):375-88, 2016.

Impact factor 3.96 Citation index 0

250. Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, Rizzi S, TrabANELLI S, OcAdLIKOVa D, Lecciso M, Giudice V, Fruet F, Urbani E, Papayannidis C, **Martinelli G**, Bandini G, Bonifazi F, Lewis RE, Cavo M, Velardi A, Lemoli RM. [Larger Size Of Donor Alloreactive Nk Cell Repertoire Correlates With Better Response To Nk Cell Immunotherapy In Elderly Acute Myeloid Leukemia Patients](#). *Clin Cancer Res*. 2016 Jan 19. [Epub ahead of print] Impact factor 8.7 Citation index 10

251. Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, **Martinelli G**, Lewis RE, Vianelli N, Cavo M, Palandri F. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. *Am J Hematol*. 92(1):37-41, 2017.

Impact factor 5 Citation index 0

252. Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, **Martinelli G**, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. *Am J Hematol*. 92(1):82-87, 2017. Impact factor 5 Citation index 0

253. Marconi C, Canobbio I, Bozzi V, Pippucci T, Simonetti G, Melazzini F, Angori S, **Martinelli G**, Saglio G, Torti M, Pastan I, Seri M, Pecci A. 5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. *J Hematol Oncol*. 18;10(1):18, 2017.

Impact factor 6.2 Citation index 0

254. **Martinelli G**, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. *J Clin Oncol*. 35(16):1795-1802, 2017.

Impact Factor 20.982 Citation index 0

255. Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, **Martinelli G**, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. *Cancer* Apr 7, 2017.

Impact factor Citation index

256. Mancini M, Castagnetti F, Soverini S, Leo E, De Benedittis C, Gugliotta G, Rosti G, Bavaro L, De Santis S, Monaldi C, Martelli M, Santucci MA, Cavo M, **Martinelli G**. FOXM1 Transcription Factor: A New Component Of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. *J Cell Biochem*. Apr 12, 2017.

Impact factor Citation index

257.Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta G, **Martinelli G**, Baccarani M, Cavo M, Rosti G, Testoni N. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. *Oncotarget*. Feb 16, 2017.

Impact factor 5 Citation index 0

258.Daniele G, Simonetti G, Fusilli C, Iacobucci I, Lonoce A, Palazzo A, Lomiento M, Mammoli F, Marsano RM, Marasco E, Mantovani V, Quentmeier H, Drexler HG, Ding J, Palumbo O, Carella M, Nadarajah N, Perricone M, Ottaviani E, Baldazzi C, Testoni N, Papayannidis C, Ferrari S, Mazza T, **Martinelli G**, Storlazzi CT. Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. *Haematologica*. Apr 14, 2017.

Impact factor 6.671 Citation index

259.Perricone M, Polverelli N, **Martinelli G**, Catani L, Ottaviani E, Zuffa E, Franchini E, Dizdari A, Forte D, Sabbatini E, Cavo M, Vianelli N, Palandri F. The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. *Oncotarget*. Mar 31, 2017.

Impact factor 5.008 Citation index

260.Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zaccaro S, Favara M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, **Martinelli G**. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories. *Oncotarget* 2017.

Impact factor 5.008 Citation index 0

261.Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pugno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, **Martinelli G**, Pane F, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party. Incidence of second primary malignancies and related mortality in imatinib-treated chronic myeloid leukemia patients. *Haematologica*. doi: 10.3324/haematol.2017.169532. [Epub ahead of print], June 2017.

Impact Factor 6.671 Citation index 0

262.Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabbatini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, **Martinelli G**, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F. Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. [Hematol Oncol](https://doi.org/10.1002/hon.2430). doi: 10.1002/hon.2430. [Epub ahead of print], May 2017.

Impact Factor 3.494 Citation index 0